Targovax and Oblique enter collaboration to target mutant RAS cancers by combining their ONCOS and Abiprot™ platforms
· Targovax and Oblique will jointly explore the feasibility and anti-cancer potential of merging their ONCOS and Abiprot technology platforms · ONCOS will be used to deliver Abiprot antibodies against hard-to-reach targets such as mutant RAS Oslo, Norway, & Gothenburg, Sweden 29 June 2020 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces that it has entered into a collaboration agreement with Oblique Therapeutics to evaluate the potential of using ONCOS oncolytic adenoviruses as a